SCHEMBL14190954

SCHEMBL14190954

Cc1ccc(CCN2CCN(C(=O)OC(C)(C)C)CC2)cn1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR4 P46093 1/20 0.47
MEN1 O00255 1/20 0.46
MAPT P10636 1/20 0.46
TSHR P16473 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GPR119 Q8TDV5 8/20 0.45
POLB P06746 1/20 0.45
CHRM2 P08172 1/20 0.44
CHRM4 P08173 1/20 0.44
CHRM1 P11229 1/20 0.44
CHRM3 P20309 1/20 0.44
ACKR3 P25106 3/20 0.44
TLR8 Q9NR97 1/20 0.42
WNT3A P56704 1/20 0.42
VEGFA P15692 1/20 0.42
EGLN1 Q9GZT9 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30520640 0.88 MEN1 (0.50) GPR4MEN1MAPTTSHRKMT2A
SCHEMBL115666 0.87 GPR119 (0.44) GPR4GPR119POLBCHRM2CHRM4
SCHEMBL14190953 0.83 MEN1 (0.50) GPR4MEN1MAPTTSHRKMT2A
SCHEMBL2850833 0.81 KDM1A (0.48) MEN1KMT2AGPR119POLBCHRM2
SCHEMBL402526 0.80 HTR1A (0.53)
SCHEMBL4572803 0.80 SIGMAR1 (0.48) MEN1MAPTKMT2ACHRM2CHRM4
SCHEMBL22800905 0.80 SIGMAR1 (0.48) MEN1MAPTKMT2ASMN1; SMN2CHRM2
SCHEMBL4832556 0.80 GPR119 (0.57) MEN1KMT2AGPR119POLBCHRM2
SCHEMBL3708001 0.80 HTR2A (0.52) CHRM2CHRM4CHRM1CHRM3
SCHEMBL2379018 0.80 THRB (0.52) MEN1KMT2ASMN1; SMN2CHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080103123-A1 New compounds BIOVITRUM (SE) 2008-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103123-A1 New compounds GPR119, GPR139, GPR180 GPR4 11/4885MEN1 2409/4885MAPT 1005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.